Vivitrol
Sponsors
New York State Psychiatric Institute, Yale University, Johns Hopkins University, University of Pennsylvania, BioCorRx Inc
Conditions
Heroin DependenceOpiate DependenceOpioid DependenceOpioid-use DisorderPrescription Opiate/Medication Dependence
Phase 1
Improved Strategies for Outpatient Opioid Detoxification
CompletedNCT01377610
Start: 2011-06-30End: 2017-12-31Updated: 2018-05-21
Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections
CompletedNCT04828694
Start: 2022-06-17End: 2023-03-22Updated: 2023-08-16
Phase 2
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
CompletedNCT00476242
Start: 2008-06-30End: 2011-08-31Updated: 2018-07-17
The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
CompletedNCT01556425
Start: 2012-05-31End: 2017-08-06Updated: 2018-03-12
CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery
CompletedNCT01587196
Start: 2012-01-31End: 2021-01-01Updated: 2024-10-15
Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
TerminatedNCT03113409
Start: 2017-06-01End: 2020-12-01Updated: 2022-03-02
Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder
TerminatedNCT04454411
Start: 2022-08-01End: 2024-08-31Updated: 2025-08-06
Phase 3
Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia
CompletedNCT01389167
Start: 2011-09-30End: 2017-05-31Target: 320Updated: 2018-01-11
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
CompletedNCT03232346
Start: 2017-08-01End: 2021-06-30Updated: 2022-11-07